Brief: Immuneering Reports Compelling Preclinical Data On Imm-1-104 At Aacr-Nci-Eortc
11/10/2021 13:09
Oct 11 (Reuters) - Immuneering Corp IMRX.O :
* IMMUNEERING REPORTS COMPELLING PRECLINICAL DATA ON
IMM-1-104 AT
AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND
CANCER THERAPEUTICS
* IMMUNEERING - ANTICIPATES SUBMISSION OF INVESTIGATIONAL
NEW DRUG
APPLICATION FOR IMM-1-104 TO U.S. FDA IN Q1 OF 2022
Source text for Eikon: ID:nGNXbH83Y7
Further company coverage: IMRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immuneering
See all newsImmuneering expects cash runway to fund operations into 2029
Immuneering posts smaller-than-expected Q1 net loss on lower R&D spend
U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT
U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners
U.S. STOCKS ON THE MOVE-Gap, Caterpillar, Solid Biosciences